Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Harnessing virus-based therapeutics and exosome targeted therapy for the treatment of pancreatic cancer
EF 2016-17
Résumé
In Canada, pancreatic cancer (PC) is the fourth leading cause of cancer-related death and is associated with a low survival ratio. This poor outcome is in part due to the fact that patients get diagnosed once the disease has reached an advanced stage. There has been little progress in the treatment of PC in the last 30 years. Current treatments include chemotherapy, but in the event of treatment failure, there is no second-line therapy available. These problems highlight the urgent need of novel PC therapeutics. Recent advances in the use of oncolytic viruses (OVs) as cancer therapeutic agents bring new hope to fight PC. OVs are unique anti-cancer bioweapons that not only have a specific predilection to infect and kill cancer cells, but that can also stimulate the immune system to fight the tumor. Virus-based therapies have shown promising benefits to cancer patients in clinical trials. However, PC resistance due to the unique biology of the tumors is the biggest challenge for developing breakthrough therapies against advanced PC. We recently found that small therapeutic RNA sequences (microRNAs) expressed from viral genomes improve PC cell killing. Those microRNAs have been shown to be packaged in small vesicles known as exosomes that can be secreted by cancer cells to reach neighboring cells and spread the tumor killing effect. The goal of this project is to create a novel OV capable of expressing a therapeutic microRNA with the capacity to enhance its loading into exosomes and producing exosomes targeted to PC cells in order to enhance the microRNA cancer cell killing effect. This project will ultimately lead to an OV with enhanced tumor cell killing potential and a greater ability to efficiently spread the tumor killing effect throughout the tumor.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367404
Name
Wedge Marie-Ève
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing virus-based therapeutics and exosome targeted therapy for the treatment of pancreatic cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Artificial Micrornas; Bioengineering; Bystander Effect; Cancer Therapeutics; Cytotoxicity; Exosomes; Oncolytic Viruses; Pancreatic Cancer; Tumor Microenvironment; Tumor Targeting Peptides
Abstract
In Canada, pancreatic cancer (PC) is the fourth leading cause of cancer-related death and is associated with a low survival ratio. This poor outcome is in part due to the fact that patients get diagnosed once the disease has reached an advanced stage. There has been little progress in the treatment of PC in the last 30 years. Current treatments include chemotherapy, but in the event of treatment failure, there is no second-line therapy available. These problems highlight the urgent need of novel PC therapeutics. Recent advances in the use of oncolytic viruses (OVs) as cancer therapeutic agents bring new hope to fight PC. OVs are unique anti-cancer bioweapons that not only have a specific predilection to infect and kill cancer cells, but that can also stimulate the immune system to fight the tumor. Virus-based therapies have shown promising benefits to cancer patients in clinical trials. However, PC resistance due to the unique biology of the tumors is the biggest challenge for developing breakthrough therapies against advanced PC. We recently found that small therapeutic RNA sequences (microRNAs) expressed from viral genomes improve PC cell killing. Those microRNAs have been shown to be packaged in small vesicles known as exosomes that can be secreted by cancer cells to reach neighboring cells and spread the tumor killing effect. The goal of this project is to create a novel OV capable of expressing a therapeutic microRNA with the capacity to enhance its loading into exosomes and producing exosomes targeted to PC cells in order to enhance the microRNA cancer cell killing effect. This project will ultimately lead to an OV with enhanced tumor cell killing potential and a greater ability to efficiently spread the tumor killing effect throughout the tumor.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wedge, Marie-Ève
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~